Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
about
Evaluation of a service development to implement the top three process indicators for quality stroke careThe economics of treating stroke as an acute brain attack.Thrombolysis ImPlementation in Stroke (TIPS): evaluating the effectiveness of a strategy to increase the adoption of best evidence practice--protocol for a cluster randomised controlled trial in acute stroke care.Adipose-derived mesenchymal stem cells markedly attenuate brain infarct size and improve neurological function in rats.Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review.The economic case for new stroke thrombolytics.Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in ChinaDesign of the economic evaluation for the Interventional Management of Stroke (III) trialCombination of cyclosporine and erythropoietin improves brain infarct size and neurological function in rats after ischemic stroke.Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke.Receptionist rECognition and rEferral of Patients with Stroke (RECEPTS): unannounced simulated patient telephone call study in primary care.Protocol for an observation and implementation study investigating optimisation of the management of stroke and transient ischaemic attack (TIA)Cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving hemodialysis.Understanding the enzymology of fibrinolysis and improving thrombolytic therapy.A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke.The cost of materials for intra-arterial thrombectomyLack of experience of intravenous thrombolysis for acute ischaemic stroke does not influence the proportion of patients treated.Setting up an acute stroke service.Stroke and thrombolysis in developing countries.Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Stem Cells in Subacute Ischemic Stroke Patients.Telemedicine in acute stroke management: systematic review.Cost-effectiveness of stroke treatments and secondary preventions.The rural Prehospital Acute Stroke Triage (PAST) trial protocol: a controlled trial for rapid facilitated transport of rural acute stroke patients to a regional stroke centre.A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischemic stroke.Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients.Improving door to CT scanner times for potential stroke thrombolysis candidates - The Emergency Department's role.Burden of stroke in Italy: an economic model highlights savings arising from reduced disability following thrombolysis.Stem cell-based therapies for ischemic stroke.The Preventive Effects of Neural Stem Cells and Mesenchymal Stem Cells Intra-ventricular Injection on Brain Stroke in Rats.Cost-effectiveness of two endovascular treatment strategies vs intravenous thrombolysis.Potential gains and costs from increasing access to thrombolysis for acute ischemic stroke patients in New Zealand hospitals.Time Gain Needed for In-Ambulance Telemedicine: Cost-Utility Model.Real-world costs of ischemic stroke by discharge status.A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.Promoting Acute Thrombolysis for Ischaemic Stroke (PRACTISE)
P2860
Q28218793-7E1E5F56-9562-441F-AA5D-361C97F23832Q33506171-3045822F-A626-43AF-9F44-14116BA6CF70Q33593063-517D141D-8F1A-4544-A117-8DBA72BAEA4FQ34035967-8CF38F71-3C76-4C1E-8933-4D583A703D5FQ34180151-BD27153D-471D-4F44-967E-250DBFD3CD9CQ34201550-294FC952-8B50-4637-904C-96BB1851A2D4Q34374190-33DFF3AC-1213-4934-8BCB-E02D31BB0447Q34644645-4256CD5C-9A71-4CAF-8859-23053F07DAFDQ35225979-A740DBA7-A450-4669-8CFF-B811FF6ED665Q35566925-FD9A22C1-425F-497D-8820-F3539B86EEC8Q35795494-91B1EACA-D07C-42AC-A7D7-970CD4BFDD5BQ36060893-FB1190C3-9206-45A2-A162-803B2788FB2DQ36130628-5ABB123E-D6F6-470D-82AE-2DC60C2C7AE2Q36156022-B461CCF2-7D8C-48A0-80FB-3D8B492A7891Q36685755-6CE7DD95-8116-4434-9A46-986656A5489BQ36696433-4E7B8B68-0CC7-4496-82DF-56F0430DFC64Q37134651-81CA1FBE-75A7-4777-B7A3-F683AE46523DQ37244411-209424C7-418B-4DE8-AEA7-22559F773A03Q37244517-1C3420BA-39FC-480E-8441-272137DCE832Q37507497-C6395B40-AA76-4642-B0C6-A63933AFCFA7Q37731008-B4654F32-8E5D-4CD1-B1D9-39B5B6F42611Q38020935-D9051B2C-7A27-4673-BC56-EFE62C2160EAQ38426621-110DEB29-2261-433D-92C9-3F0B9D1BE595Q38665544-22659046-7CCE-4195-8B36-B4D775C468DEQ40572852-D210B75D-529D-4DEE-8FB8-57BEC8074638Q41097928-4216A867-5E14-46CC-8E27-24419EC3A700Q41100489-840F4767-EDA3-4814-BC9E-7026CEF78127Q41928171-BF783553-544C-43AD-9B7F-7E4459B7FBB3Q41995551-F3DA788F-9ECD-454B-9FE2-9BA4BA54D0F4Q45113409-F30EACC7-0489-403C-9DDE-5C9A90C97F85Q45393906-40613BCF-1DEA-43A1-9C53-11ECF1E8A1BEQ47130483-8A34676C-B1B6-45EA-955C-147FD658ABFAQ48435681-5D49FC0E-8697-4382-97B8-022A04EA8AA1Q48492472-A0A5C144-057F-450D-9A48-3B651CC8E198Q58476485-673F5B76-3891-4FD2-9F0A-DE7877BC0DB7
P2860
Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cost-effectiveness of thrombol ...... a model based on UK NHS costs.
@ast
Cost-effectiveness of thrombol ...... a model based on UK NHS costs.
@en
type
label
Cost-effectiveness of thrombol ...... a model based on UK NHS costs.
@ast
Cost-effectiveness of thrombol ...... a model based on UK NHS costs.
@en
prefLabel
Cost-effectiveness of thrombol ...... a model based on UK NHS costs.
@ast
Cost-effectiveness of thrombol ...... a model based on UK NHS costs.
@en
P2093
P1433
P1476
Cost-effectiveness of thrombol ...... a model based on UK NHS costs.
@en
P2093
Aileen Neilson
Eivind Berge
John Forbes
Joseph Kwan
Martin Dennis
Peter Hand
Peter Sandercock
Richard Lindley
Steff Lewis
P304
P356
10.1161/01.STR.0000126871.98801.6E
P407
P577
2004-04-22T00:00:00Z